The comparison between Olanzapine- Aprepitant- Granisetron effects on chemotherapeutic drug induced nausea and vomiting in patients

Determine and comparison between Olanzapine- Aprepitant- Granisetron effects on chemotherapeutic drug induced nausea and vomiting in patients of Ali Ibn Abitaleb Hospital

This is a Phase 3 clinical trial with parallel, blind and randomized groups. First, qualified samples enter in Convenient non-randomly method, then they'll be allocated into one of three groups of Olanzapine- Aprepitant- Granisetron using permuted block randomization method.

Study population included patients in Ali Ibn Abitaleb Hospital (Zahedan) undergoing chemotherapy. After grouping, groups are randomly named 1, 2 and 3, and corresponding assistant who records patients clinical information, as well as patients, will be blinded for drug names.

Inclusion criteria: Informed consent, Receiving chemotherapy regimens with moderate-high nausea and vomiting, Serum Creatinine 2 or less, Not having another cause for nausea and vomiting like stomach cancer. exclusion criteria: Having uncontrollable nausea and vomiting, Having allergies or other medications side effects, Pregnant and lactating women, Use other interventions or confusing drugs (Quinolones, other underlying conditions ,etc.), Having nausea and vomiting 24 hours before treatment.

Group1: 5 mg Oral Olanzapine daily in 3 days Group2: Kytril tablet 2 mg+ 125 mg oral Aprepitant on day one, 80 mg in second and third day Group3: 1 g Granisetron ampoules daily in 3 days

Nausea and vomiting of chemotherapy

Sampling will be randomized with the help of permutation blocks. At first, the eligible samples will enter the study in easily or accessible method, then using randomized block method, they'll enter in one of the three study groups.

We will explain to patients that according to the use of double blind technique, the type of drug used and the group which they are placed will not be informed to them, and if they do not accept, they will not be included in the study. After treatment, patients will be monitored for nausea and vomiting on the first day and 48 to 72 hours after chemotherapy and their clinical data will be recorded. During the study and after grouping, the groups are randomly named 1, 2, and 3, and the corresponding assistant who records the patients' clinical information, as well as the patients, will not be involved in the medications used by the name of the drugs. The main researcher will not be blinded.